First Time Loading...

Pharma Mar SA
OTC:PHMMF

Watchlist Manager
Pharma Mar SA Logo
Pharma Mar SA
OTC:PHMMF
Watchlist
Price: 31.15 USD 16.01% Market Closed
Updated: May 7, 2024

Intrinsic Value

Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. [ Read More ]

The intrinsic value of one PHMMF stock under the Base Case scenario is 39.03 USD. Compared to the current market price of 31.15 USD, Pharma Mar SA is Undervalued by 20%.

Key Points:
PHMMF Intrinsic Value
Base Case
39.03 USD
Undervaluation 20%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Pharma Mar SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling PHMMF stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Pharma Mar SA

Provide an overview of the primary business activities
of Pharma Mar SA.

What unique competitive advantages
does Pharma Mar SA hold over its rivals?

What risks and challenges
does Pharma Mar SA face in the near future?

Summarize the latest earnings call
of Pharma Mar SA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Pharma Mar SA.

Provide P/S
for Pharma Mar SA.

Provide P/E
for Pharma Mar SA.

Provide P/OCF
for Pharma Mar SA.

Provide P/FCFE
for Pharma Mar SA.

Provide P/B
for Pharma Mar SA.

Provide EV/S
for Pharma Mar SA.

Provide EV/GP
for Pharma Mar SA.

Provide EV/EBITDA
for Pharma Mar SA.

Provide EV/EBIT
for Pharma Mar SA.

Provide EV/OCF
for Pharma Mar SA.

Provide EV/FCFF
for Pharma Mar SA.

Provide EV/IC
for Pharma Mar SA.

Show me price targets
for Pharma Mar SA made by professional analysts.

What are the Revenue projections
for Pharma Mar SA?

How accurate were the past Revenue estimates
for Pharma Mar SA?

What are the Net Income projections
for Pharma Mar SA?

How accurate were the past Net Income estimates
for Pharma Mar SA?

What are the EPS projections
for Pharma Mar SA?

How accurate were the past EPS estimates
for Pharma Mar SA?

What are the EBIT projections
for Pharma Mar SA?

How accurate were the past EBIT estimates
for Pharma Mar SA?

Compare the revenue forecasts
for Pharma Mar SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Pharma Mar SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Pharma Mar SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Pharma Mar SA compared to its peers.

Compare the P/E ratios
of Pharma Mar SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Pharma Mar SA with its peers.

Analyze the financial leverage
of Pharma Mar SA compared to its main competitors.

Show all profitability ratios
for Pharma Mar SA.

Provide ROE
for Pharma Mar SA.

Provide ROA
for Pharma Mar SA.

Provide ROIC
for Pharma Mar SA.

Provide ROCE
for Pharma Mar SA.

Provide Gross Margin
for Pharma Mar SA.

Provide Operating Margin
for Pharma Mar SA.

Provide Net Margin
for Pharma Mar SA.

Provide FCF Margin
for Pharma Mar SA.

Show all solvency ratios
for Pharma Mar SA.

Provide D/E Ratio
for Pharma Mar SA.

Provide D/A Ratio
for Pharma Mar SA.

Provide Interest Coverage Ratio
for Pharma Mar SA.

Provide Altman Z-Score Ratio
for Pharma Mar SA.

Provide Quick Ratio
for Pharma Mar SA.

Provide Current Ratio
for Pharma Mar SA.

Provide Cash Ratio
for Pharma Mar SA.

What is the historical Revenue growth
over the last 5 years for Pharma Mar SA?

What is the historical Net Income growth
over the last 5 years for Pharma Mar SA?

What is the current Free Cash Flow
of Pharma Mar SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Pharma Mar SA.

Financials

Balance Sheet Decomposition
Pharma Mar SA

Current Assets 252.6m
Cash & Short-Term Investments 162.6m
Receivables 27.6m
Other Current Assets 62.5m
Non-Current Assets 87.9m
Long-Term Investments 6.9m
PP&E 47.6m
Intangibles 1.9m
Other Non-Current Assets 31.5m
Current Liabilities 95.9m
Accounts Payable 31.3m
Other Current Liabilities 64.6m
Non-Current Liabilities 51.2m
Long-Term Debt 28.9m
Other Non-Current Liabilities 22.3m
Efficiency

Earnings Waterfall
Pharma Mar SA

Revenue
158.2m EUR
Cost of Revenue
-9.6m EUR
Gross Profit
148.5m EUR
Operating Expenses
-152.6m EUR
Operating Income
-4.1m EUR
Other Expenses
5.2m EUR
Net Income
1.1m EUR

Free Cash Flow Analysis
Pharma Mar SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

PHMMF Profitability Score
Profitability Due Diligence

Pharma Mar SA's profitability score is 64/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional 3-Year Average ROIC
Positive Gross Profit
Negative Free Cash Flow
64/100
Profitability
Score

Pharma Mar SA's profitability score is 64/100. The higher the profitability score, the more profitable the company is.

PHMMF Solvency Score
Solvency Due Diligence

Pharma Mar SA's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
High Altman Z-Score
Short-Term Solvency
63/100
Solvency
Score

Pharma Mar SA's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PHMMF Price Targets Summary
Pharma Mar SA

Wall Street analysts forecast PHMMF stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PHMMF is 52.05 USD with a low forecast of 29.47 USD and a high forecast of 72.45 USD.

Lowest
Price Target
29.47 USD
5% Downside
Average
Price Target
52.05 USD
67% Upside
Highest
Price Target
72.45 USD
133% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

PHM Price
Pharma Mar SA

1M 1M
+13%
6M 6M
-9%
1Y 1Y
-16%
3Y 3Y
-63%
5Y 5Y
+33%
10Y 10Y
+1%
Annual Price Range
31.6
52w Low
26.24
52w High
43.74
Price Metrics
Average Annual Return 37.62%
Standard Deviation of Annual Returns 52.65%
Max Drawdown -80%
Shares Statistics
Market Capitalization 557.4m EUR
Shares Outstanding 18 176 100
Percentage of Shares Shorted
N/A

PHM Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Pharma Mar SA Logo
Pharma Mar SA

Country

Spain

Industry

Biotechnology

Market Cap

557.4m EUR

Dividend Yield

2.22%

Description

Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. The company is headquartered in Colmenar Viejo, Madrid and currently employs 477 full-time employees. The company went IPO on 2015-11-02. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The firm is active globally.

Contact

MADRID
Colmenar Viejo
Avda. De los Reyes, 1, Pol. Ind. La Mina
+34918466000.0
https://www.pharmamar.com/es/

IPO

2015-11-02

Employees

477

Officers

Founder, Executive Chairman, CEO & President
Mr. Jose Maria Fernandez Sousa-Faro Ph.D.
Executive Vice-Chairman
Mr. Pedro Francisco Fernandez Puentes
Founder
Mr. Juan Carlos-Torres Carretero
Chief Financial Officer
Ms. María Luisa de Francia Caballero
Director of Capital Markets & Investor Relations
Mr. José Luis Moreno Martinez-Losa
General Counsel & Secretary of the Board of Directors
Mr. Juan Gomez Pulido
Show More
Global Compliance Head
Ms. Sandra Llamera Sanchez
Communication Director
Ms. Lara Vadillo
Director of Corporate Development
Ms. Belén Sopesén Veramendi Ph.D.
Director of Human Resources & IT
Mr. Luis Rupérez Cuenca
Show Less

See Also

Discover More
What is the Intrinsic Value of one PHMMF stock?

The intrinsic value of one PHMMF stock under the Base Case scenario is 39.03 USD.

Is PHMMF stock undervalued or overvalued?

Compared to the current market price of 31.15 USD, Pharma Mar SA is Undervalued by 20%.